Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Treatment combinations in BRAF-mutant metastatic melanoma.]

Recenti progressi in medicina - 1 Apr 2021

Depenni Roberta

Abstract excerpt

Combinations of BRAF and MEK inhibitors are now the standard treatment in patients with BRAF V600-mutant metastatic melanoma. Three combination treatments with BRAF and MEK inhibitors are available for thetreatment of metastatic melanoma: vemurafenib + cobimetinib, dabrafenib + trametinib, encorafenib + binimetinib. These 3 combination treatments have distinct safety profiles as evidenced by the data from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials, Phase III as Topic
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 33877098
DOI: 10.1701/3584.35696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Treatment combinations in BRAF-mutant metastatic melanoma.]PMID 33877098Read ↗

[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].Semantic proximity Read ↗

[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.